Quince Therapeutics, Inc.
QNCXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How QNCX's past catalysts played out
EryDex Low dose DSP
Nervous System Disease
Dexamethasone sodium phosphate
Ataxia Telangiectasia
Dex 21-P
Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EryDex Low dose DSP | Phase 3 | Nervous System Disease | - | - |
Dexamethasone sodium phosphate | Phase 3 | Ataxia Telangiectasia | - | - |
Dex 21-P | Phase 2 | Ulcerative Colitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Quince Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Quince Therapeutics, Inc.'s (QNCX) pipeline across Phase 3, Phase 2. Its lead program is EryDex Low dose DSP (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Quince Therapeutics, Inc.'s next FDA catalyst?→
Quince Therapeutics, Inc.'s (QNCX) next tracked catalyst is a Phase 3 expected November 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track QNCX biotech catalysts?→
Add QNCX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Quince Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.